Check out Friday's dose of biotech's news of note.

Feinstein Institute-led researchers used an Alzheimer’s drug to reduce inflammation in people with metabolic syndrome.

Staffers are set to move to their new digs in east London in the middle of next year, shortly the EMA is scheduled to leave a neighboring building.

Targeting a cell process that promotes protein clumping could lead to new drugs for ALS.

In this week's EuroBiotech Report, Roche dumps Oryzon, Sanofi and Shire strike deals with European biotechs, and more.

Belgian biotech Ablynx signed a deal with Sanofi that could be worth an eye-watering €2.4 billion, although just €23 million of that comes up front.

In our EuroBiotech roundup this week, 4SC out-licenses Kv1.3 inhibitors, One Nucleus names CEO and Paion raises €8 million. 

The dumping of LSD1 inhibitor ORY-1001 wiped as much as 30% off Oryzon’s stock price as investors digested the loss of the $500 million-plus deal.

NeuroVia gets $14 million to treat rare CNS disorder X-linked adrenoleukodystrophy.